Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)

Inclusion Criteria: 1. Male and female subjects between the age of 18 to 75 years 2. Subjects with renal anaemia (haemoglobin 7.5 g/dl to 10 g/dl) 3. Subjects who are treatment naïve to epoetin 4. Subjects with chronic kidney disease (CKD) stages\* 3 and 4 not yet on dialysis (predialysis) 5. Subjects willing to provide a written informed consent 6. Subjects with serum ferritin ≥ 100 μg/L and/or transferrin saturation ≥ 20% * CKD staging will be based on the five-stage system for classification of CKD based on KDIGO guidelines. Exclusion Criteria: 1. Subjects with anaemia due to other reasons (that is not renal anaemia) 2. Subjects on dialysis 3. Subjects who have undergone blood transfusion within the last 3 months 4. Subjects with major complication such as severe/chronic infections or bleeding, or aluminum toxicity 5. Subjects with suspected or known PRCA 6. Subjects with a history of aplastic anaemia 7. Subjects with uncontrolled diabetes (fasting blood glucose \> 240 mg/dl) or uncontrolled hypertension (systolic blood pressure \> 180 mm Hg, diastolic blood pressure \> 110 mm Hg) 8. Subjects with known hypersensitivity to any of the ingredients of the investigational products, the mammalian cell-derived product or human albumin products 9. Subjects with history of seizure disorder 10. Subjects with hematological disorder (thrombocytopenia, neutropenia, or hemolysis) 11. Subjects with hyperparathyroidism (intact parathyroid hormone \> 1000 pg/ml) 12. Subjects with severe liver dysfunction 13. Subjects with congestive heart failure and/or angina (NYHA class III and IV) 14. Subjects with myocardial infarction or stroke in the preceding 6 months of screening 15. Subjects with active malignancy in the previous 5 years 16. Subjects with gastrointestinal bleeding in the past 6 months 17. Subjects with immunosuppressive therapy in the previous 3 months 18. Subjects with Hepatitis B virus (HbsAg), Hepatitis C virus (HCV), Human Immunodeficiency Virus (HIV) and syphilis 19. Female subjects who are pregnant, breast-feeding,planning to be pregnant during the study, or women of child-bearing potential (any woman who is not surgically sterile i.e. bilateral tubal ligation, total hysterectomy or \< 2 years post menopause) not using a reliable method of double contraception (e.g. condom plus diaphragm, condom or diaphragm plus spermicidal gel/foam, tubal ligation, or stable dose of hormonal contraception) throughout the study period 20. Subjects participating in trials involving erythropoietin in the past 6 months before screening 21. Subjects currently participating or participation in an investigational study within 30 days prior screening